San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor within the weight loss drug sector in February right after revealing promising information from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection and in March